were Thank and We with strategy of ADHD multi-brand for portfolio, you, and commercial everyone. to our driving goal were entered NTXXXX, profitability. XXXX as to and met was company strategy the a the net per well XXXX. pilot welcome improving commencing increasing committed the operating our in and our commercial with filing all advancing a on we Rich, the organization. an transformative access At Neos. revenue same pack new lead development year focused patient We also X as PK our of Phase time, closer study IND program optimizing goal to
what proud the For of Neos. we future our able and of means business, I'm achieve to for so commercial were this what
to XXXX loss than more compared reduced expenses to $XX our compared $XX to to per and by our in XX% key in were million pack our realize million improved XXXX which by and we First, sales improvement revenue a drivers approximately XXXX. compared operating ability net marketing XXXX, in
RxConnect. reached have and pharmacies. an to year, network the build now XXX pharmacies we Second, And report, patient the of approximately the new of to today, had entirely Neos able were we XXX best-in-class we end I'm by support as program pleased in
tremendous by ADHD net accomplishments a a achievement set smaller prescription. XX% products is abandon These able with force we Third, to And constant portion XXXX a as that force unprofitable meaningful contracts our smaller were prescriptions considering to significantly in drove sales XXXX. able our decision This sales lower have and we for to increase programs of total our our hold entered sales XXXX for XXXX. despite and XXXX to compared a strong and finally, and sales XXXX. expenses, were foundation marketing we of Neos products successfully in financial
their believe now RxConnect is support greater We seeing best-in-class Neos evidence be for insured continue possible can that predictability individual is to commercially to for plan. co-pay This Neos-sponsored lowest a our regardless create the patient and significant driver patients, in are program and business. insurance of designed
believe most frustrations was they feedback health RxConnect following XXXX for otherwise early HCPs be prescribing in care created from in their medications in-depth the appropriate and Neos research as about patients. to what professionals, known their
not are their widely their hassle in frustration, well pharmacy to for resulting at variable callbacks patient an and medications the HCP often patients is and office additional unpredictable to and as leads and complaints which HCP for or the as Too work the available co-pay staff.
the For year. Neos these we and reasons, created then it RxConnect throughout scaled rapidly up a
brands RxConnect and importantly, program tremendous the competition presents ADHD Neos for our and Most this believe barrier replicate. value differentiates to from convenience high to customers. both Neos believe others truly our We a offers we and
in sales of team. We and our working committed with manager sales to increase and – to internal this with RxConnect account dedicated are field expand pharmacists that team to added Neos efforts an regional our supporting both adoption and continuing program, recently is to invest by
from the more promising. mid-December, that a than early customer at network service pharmacy. regional XXXX, have results and across reputation loyalty H-E-B areas unsurpassed the it the the are in approximately with Texas, within were pharmacy end in there XXX and became pharmacies partnership mentioned grocery active in As key and for RxConnect XXX H-E-B an this I including stores chain and network, Neos of a
prescriptions X.X% ADHD over XXXX. nationwide Neos XXXX, January grew December In
Neos the partnership addition the More state United of week recently, chain XX.X% these the has XXX national mid-western Texas, that in our just of the across than XXXX. increasing increased by doubled through pharmacy of pharmacies percentage across However finalized in another the January in prescriptions spread in over XX% are regional the with total number we December more Neos pharmacies region network RxConnect States. that key markets the this growth
meeting week yesterday. this pharmacies we with In went launch force the and held just sales fact, live our the
are growth in chains discussions force our addition Neos that XXXX. the we various and to early throughout an sales interest an from that can footprint to our additional of be additional Finally, Neos of expect RxConnect results belief with align relationship expand the These RxConnect regional engine our with regional for continue chains and business. H-E-B of our from bolster stages
the are where As of We we prescribing. key many resources revenue and we of deployed net force on sales pack enhanced with you prescription a specialists a have focus increase believe we accounts tools of of we territory XX to specialty that operating generate. targeting breadth and and know, approximately overall continue quality commercial per metric of depth measure volume the the can performance a use a as with
$XXX, net pack a revenue over in one XXXX. to ago. approximately business in year XXXX profitability, quarter pack from operational by This fourth quarter significant to saw made the net was XXXX we revenue reflects the as XX% Cotempla towards strides XX% $XX was a revenue XXXX. per same pack XR-ODT, net the increased per the XX% quarter XXXX increase in over $XXX, per of same continued $XXX in for Adzenys our For shift growth increase And for XR-ODT, we
address inability is treatment believe the lead to a development for neurological need high exhibit an to a mental and than excessive pipeline. one-third tremendous development our with saliva. NTXXXX, to now chronic sialorrhea, our asset with Parkinson's potential more due that candidate unmet retardation, as of of condition patients cerebral drooling where swallow a disease, We Turning the to the such conditions palsy, ALS sufficiently
States the patients due X.X the patients too results and challenges treatment-limiting Approximately condition, socially. associated currently most report severe available patients treatment in medically on and left being this associated this treatments. to suffer side in million basis effects both only experience physicians an to dosing the with This and condition reserve for they complex that many regimens with United with annual
treatment both dosing adult study Phase of in formulations only volunteers, with their attributes that NTXXXX successfully profile into our profile regimen. to us to a NTXXXX millions pilot develop the patients new give the advance an product is We formulation healthy twice confidence once improved tested potential of of we as these we tolerability key and met NTXXXX daily. the of administered promise of demonstrated to the offers many be pharmacokinetic orally I NTXXXX formulations evaluating all NTXXXX option the dosed In that and an for plan to multiple and further the study caregivers objectives clinical development. likely XX or the of
and ascending bioavailability for multi-part allow ascending healthy step concentrations Phase half this to will us I study and clinical study of I XXXX. plasma Phase the compare normal The a in oral second This initiate cohorts dose volunteers. compound. trial parent include to to next will is single enroll The the and program multiple
disorders to can that well Neos also commercial burden. complement existing CNS, are as a franchise. that address opportunities, has model applicability disease we RxConnect there product as neurological overall with on advanced platform would confident These we is opportunities, additional addition, symptoms seek continue and we we In ADHD our the exacerbate with our leverage focus opportunities beyond portfolio, existing analytics our where associated with believe large a to our opportunity
remarks, closing discuss COVID-XX the ongoing a moment coronavirus to to my threat. take I Before or wanted
our from We'll supply be very examining what chain our to our monitoring actively a manufacturing sales everyone business for of a the all and like aspects chain. to understand believe are We based force reliable of our audit situation. this to plant is best field as we time, of obviously for suppliers, fluid upon that further have a possible as theirs an as well plan we deterioration At as situation. supply
inventory standpoint, in hand have in that the located approximately chain. we believe we with additional average four retail months an inventory on on and is that wholesalers From
build are to disruption. our levels protect future seeking to We further against help inventory
force, the of our safety their and sales employees, highest health With of concern. respect and patients to customers field-based is our our
Ultimately, the time. period may are access in of representatives local to customer authorities. respect monitor, geography, our government our and some for sales understand and restrictions and health this policies representatives our We to instructing of result for in customers some
from current the In benefit over the but accessible future focus want I turn may it treatments on of With that them, are as only also a lives conclusion, well on care readily our to improve our that we Rich, touch at their health as seeking professionals products patients. to not here Neos. before to patients to want to vision ensure patients, I
with to stage great We poised are off our development. to XXXX and NTXXXX in next ADHD start is advance the clinical into business a of
you today to look and to over progress updating forward you it for your Rich. we on Turn and our Thank soon. time interest
